Inclusion Criteria:

          -  Diagnosed with histologically confirmed adenocarcinoma of the prostate based on
             core-biopsy within 1 year of study entry from TRUS

          -  Clinical stages T1c to T2c

          -  PSA <20, within 6 months of study entry

          -  Participants who are currently receiving Dutasteride (or have received it within the
             last 90 days) or Finasteride (or have received it within the last 30 days) must have a
             PSA of ≤ 10

          -  Gleason score ≤6, 3 + 4 = 7, or 4 + 3 = 7

          -  ECOG Performance Status 0-1 as documented within 3 months prior to study entry

          -  Must have complete history and physical examination within 45 days of study entry and
             digital rectal examination of prostate within 180 days of study entry

        Exclusion Criteria:

          -  Prior surgery (not including TURP), cryosurgery, radiofrequency ablation, chemotherapy
             or radiation for PCa

          -  Prior or planned androgen deprivation or bilateral orchiectomy

          -  Distant metastases, or clinically or pathologically involved lymph nodes confirmed by
             a CT scan within 365 days of study entry

          -  Hip prosthesis, inflammatory bowel disease or connective tissue disorder such as
             active scleroderma or lupus

          -  Individuals with a history of other malignancies are ineligible unless 1) they have
             been disease-free for at least 5 years OR 2) are deemed by the investigator to be at
             low risk for recurrence of that malignancy with no plans for adjuvant systemic
             chemotherapy and/or radiation therapy and have received overall principal investigator
             approval.

          -  Individuals who have AIDS (CD4 < 200 or an AIDS-defining illness) or are HIV positive
             and not on HAART therapy are ineligible.

          -  Major medical or psychiatric illness

          -  Individuals with any of the following conditions are excluded from this study:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months.

               -  Transmural myocardial infarction within the last 6 months.

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration.

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of registration

               -  History of Hepatic insufficiency resulting in clinical jaundice and/or
                  coagulation defects within the last 12 months